Patients battling Glioblastoma (CBM), the most common and deadliest form of primary brain cancer, have a new FDA-approved option for therapy that is now being offered at The Adena Cancer Center.
Optune® is a portable medical device that enables the patient to go about their daily activities while receiving treatment for GBM. It is the first FDA-approved therapy in more than a decade for newly diagnosed GBM.
“Our goal is to treat cancer patients with the latest, approved therapies available, so we are pleased to add Optune® as part of a combination treatment for those fighting GBM,” said Adena Cancer Center Medical Director Dr. Alex Wilson. “We also know how important quality of life is for our patients, and Optune® is a therapy that allows patients to go about their daily activities with minimal disruption to their day-to-day lives.”
For newly-diagnosed patients, Optune® is used in combination with their chemotherapy. In
clinical trials, adding Optune® as a form of treatment has proven to delay GBM tumor growth, and extend survival in newly-diagnosed patients compared with chemotherapy alone. Other benefits for patients include lessening the effects of chemotherapy, which can include: fewer infections, less nausea, decreased incidences of diarrhea and lowered blood counts.
The lightweight Optune® device is worn on the patient’s head and creates low-intensity electric fields to slow or stop GBM cancer cells from dividing, and may also cause some of the cancerous cells to die. Patients are free to wear loose-knit wigs, hats and head coverings over the device, allowing them to conduct their daily activities with confidence.
For more information on Optune and the Adena Cancer Center, visit adena.org/optune or call 740-542-3030.